Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: M05BX

Evenity(romosozumab)

Osteoporosis

Marketing Authorisation Holder: UCB Pharma S.A.

EMA Authorisation: 09/12/2019

INN: romosozumab

Indication

Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Evenity — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.